Corneal Cross-linking gets second orphan drug status approval
Tagged with: Corneal Cross Linking | Keratoconus | Ectasia | Acos Topcon | Orphan Drug |
Dr. Holzman will be one of the principal investigators in a clinical study for corneal cross-linking which means that we will be able to help patients with keratoconus or post-refractive surgery ectasia all over the Maryland - DC - Virginia region.
